NorthStar Medical Radioisotopes, LLC (‘NorthStar’), engaged in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), a major manufacturer in particle accelerator technology, have announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.
The
accelerator will be exclusively used for the production of no-carrier added
(n.c.a.) actinium-225 (Ac-225), an important therapeutic radioisotope that is
in highly limited supply and for which no commercial-scale production
technology currently exists. NorthStar previously purchased two Rhodotron®
accelerators from IBA for its newly completed molybdenum-99 (Mo-99) production
facility.
The
final stage of facility design is underway for NorthStar’s state-of-the-art Therapeutic
Radioisotope production facility, which will be exclusively dedicated to Ac-225
production, with construction scheduled to begin in early 2022. Initial
production of Ac-225 is planned for late 2023, and a Drug Master File is
expected to be submitted to the FDA in 2024. NorthStar’s proprietary process for the
production of Ac-225 will use IBA’s Rhodotron® to enable commercial-scale
n.c.a. Ac-225 production that is free of long-life radioactive byproducts
associated with other production methods.
To
read more please visit:
Source: NorthStar